See more : TOYO Co., Ltd. (TOYO) Income Statement Analysis – Financial Results
Complete financial analysis of Quest Diagnostics Incorporated (DGX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Quest Diagnostics Incorporated, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Firebird Metals Limited (FRB.AX) Income Statement Analysis – Financial Results
- GUANGDONG DECRO FI (001378.SZ) Income Statement Analysis – Financial Results
- Sri Lakshmi Saraswathi Textiles (Arni) Limited (SLSTLQ.BO) Income Statement Analysis – Financial Results
- Progressive Care, Inc. (RXMD) Income Statement Analysis – Financial Results
- ARGO Properties N.V. (ARGO.TA) Income Statement Analysis – Financial Results
Quest Diagnostics Incorporated (DGX)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.questdiagnostics.com
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.25B | 9.88B | 10.79B | 9.44B | 7.73B | 7.53B | 7.71B | 7.52B | 7.49B | 7.44B | 7.15B | 7.38B | 7.51B | 7.37B | 7.46B | 7.25B | 6.70B | 6.27B | 5.50B | 5.13B | 4.74B | 4.11B | 3.63B | 3.42B | 2.21B | 1.46B | 1.53B | 1.62B |
| Cost of Revenue | 6.29B | 6.45B | 6.58B | 5.80B | 5.04B | 4.93B | 4.72B | 4.62B | 4.66B | 4.64B | 4.33B | 4.36B | 4.40B | 4.32B | 4.32B | 4.26B | 3.97B | 3.70B | 3.26B | 2.99B | 2.77B | 2.43B | 2.15B | 1.97B | 1.32B | 813.90M | 875.50M | 1.01B |
| Gross Profit | 2.96B | 3.43B | 4.21B | 3.63B | 2.69B | 2.61B | 2.99B | 2.90B | 2.84B | 2.80B | 2.82B | 3.02B | 3.12B | 3.05B | 3.13B | 2.99B | 2.74B | 2.57B | 2.25B | 2.14B | 1.97B | 1.68B | 1.48B | 1.45B | 886.20M | 644.70M | 653.20M | 605.42M |
| Gross Profit Ratio | 32.00% | 34.74% | 39.02% | 38.50% | 34.80% | 34.59% | 38.79% | 38.58% | 37.85% | 37.63% | 39.46% | 40.88% | 41.48% | 41.41% | 42.03% | 41.29% | 40.79% | 41.04% | 40.82% | 41.66% | 41.57% | 40.79% | 40.69% | 42.49% | 40.19% | 44.20% | 42.73% | 37.46% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.42B | 1.75B | 1.68B | 1.68B | 1.73B | 1.70B | 1.75B | 1.81B | 1.71B | 1.75B | 1.74B | 1.61B | 1.43B | 1.26B | 1.23B | 1.17B | 1.07B | 1.02B | 1.00B | 643.40M | 481.60M | 502.10M | 495.32M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -15.00K | 27.00K | -18.00K | -34.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.62B | 1.87B | 1.73B | 1.55B | 1.46B | 1.42B | 1.75B | 1.68B | 1.68B | 1.73B | 1.70B | 1.75B | 1.81B | 1.71B | 1.75B | 1.74B | 1.61B | 1.43B | 1.26B | 1.23B | 1.17B | 1.07B | 1.02B | 1.00B | 643.40M | 481.60M | 502.10M | 495.32M |
| Other Expenses | 0.00 | 131.00M | 101.00M | 112.00M | 1.00M | -8.00M | 16.00M | -48.00M | -143.00M | 4.00M | 8.00M | 6.70M | 305.79M | 48.47M | 27.04M | 33.98M | 30.87M | 10.91M | 20.49M | 6.70M | 8.20M | 8.37M | 46.11M | 134.30M | 90.80M | 68.80M | 76.40M | 711.38M |
| Operating Expenses | 1.76B | 2.01B | 1.83B | 1.66B | 1.46B | 1.50B | 1.83B | 1.74B | 1.77B | 1.82B | 1.82B | 1.82B | 2.12B | 1.76B | 1.77B | 1.77B | 1.64B | 1.44B | 1.28B | 1.23B | 1.17B | 1.08B | 1.06B | 1.14B | 734.20M | 550.40M | 578.50M | 1.21B |
| Cost & Expenses | 7.94B | 8.46B | 8.41B | 7.47B | 6.50B | 6.43B | 6.54B | 6.36B | 6.43B | 6.45B | 6.15B | 6.18B | 6.52B | 6.07B | 6.10B | 6.03B | 5.61B | 5.14B | 4.54B | 4.23B | 3.94B | 3.52B | 3.22B | 3.10B | 2.05B | 1.36B | 1.45B | 2.22B |
| Interest Income | 11.00M | 10.00M | 1.00M | 3.00M | 5.00M | 2.00M | 2.00M | 1.00M | 1.00M | 3.00M | 3.00M | 3.00M | 2.77M | 1.41M | 2.52M | 5.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 163.00M | 138.00M | 151.00M | 163.00M | 175.00M | 167.00M | 151.00M | 143.00M | 153.00M | 164.00M | 159.00M | 164.70M | 170.60M | 146.10M | 144.10M | 185.48M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 439.00M | 437.00M | 408.00M | 361.00M | 329.00M | 309.00M | 270.00M | 249.00M | 304.00M | 314.00M | 283.00M | 286.60M | 281.10M | 254.00M | 256.70M | 264.60M | 237.88M | 197.40M | 176.12M | 168.73M | 153.90M | 131.39M | 147.73M | 134.30M | 90.80M | 68.80M | 76.40M | 99.10M |
| EBITDA | 1.73B | 1.82B | 3.16B | 2.41B | 1.59B | 1.40B | 1.45B | 1.48B | 1.56B | 1.30B | 1.79B | 1.52B | 1.30B | 1.59B | 1.63B | 1.50B | 1.33B | 1.33B | 1.18B | 1.05B | 950.36M | 723.84M | 559.12M | 452.11M | 242.80M | 163.10M | 151.10M | -502.19M |
| EBITDA Ratio | 18.72% | 18.31% | 29.27% | 25.52% | 20.45% | 18.67% | 18.82% | 18.10% | 20.82% | 17.85% | 18.42% | 20.58% | 17.38% | 21.43% | 22.12% | 21.25% | 19.88% | 21.27% | 21.20% | 21.07% | 19.99% | 17.17% | 15.37% | 13.32% | 14.46% | 11.66% | 13.34% | -31.07% |
| Operating Income | 1.26B | 1.43B | 2.38B | 1.97B | 1.23B | 1.10B | 1.17B | 1.28B | 1.40B | 983.00M | 1.48B | 1.20B | 995.00M | 1.30B | 1.36B | 1.22B | 1.09B | 1.13B | 968.11M | 901.44M | 795.43M | 592.45M | 411.39M | 317.82M | 152.00M | 94.30M | 74.70M | -601.28M |
| Operating Income Ratio | 13.64% | 14.45% | 22.07% | 20.89% | 15.93% | 14.62% | 15.11% | 16.99% | 18.67% | 13.22% | 20.64% | 16.27% | 13.25% | 17.58% | 18.23% | 16.86% | 16.28% | 17.99% | 17.59% | 17.58% | 16.79% | 14.42% | 11.34% | 9.29% | 6.89% | 6.47% | 4.89% | -37.20% |
| Total Other Income/Expenses | -132.00M | -193.00M | 218.00M | -87.00M | -155.00M | -175.00M | -135.00M | -142.00M | -101.00M | -134.00M | 192.00M | -133.00M | -130.77M | -99.28M | -131.18M | -203.42M | -178.93M | -94.73M | -57.66M | -76.55M | -58.66M | -50.07M | -114.80M | -116.84M | -137.60M | -40.40M | -93.80M | -74.92M |
| Income Before Tax | 1.13B | 1.24B | 2.60B | 1.88B | 1.08B | 926.00M | 1.03B | 1.09B | 1.10B | 849.00M | 1.35B | 1.07B | 856.30M | 1.18B | 1.23B | 1.02B | 912.40M | 1.03B | 910.45M | 835.13M | 737.80M | 542.38M | 332.60M | 200.98M | 14.40M | 53.90M | -19.10M | -676.20M |
| Income Before Tax Ratio | 12.21% | 12.50% | 24.09% | 19.96% | 13.93% | 12.30% | 13.36% | 14.45% | 14.72% | 11.42% | 18.86% | 14.47% | 11.40% | 16.07% | 16.47% | 14.06% | 13.61% | 16.48% | 16.54% | 16.29% | 15.57% | 13.20% | 9.17% | 5.87% | 0.65% | 3.70% | -1.25% | -41.84% |
| Income Tax Expense | 248.00M | 264.00M | 597.00M | 460.00M | 247.00M | 182.00M | 241.00M | 429.00M | 373.00M | 262.00M | 500.00M | 401.90M | 349.00M | 425.50M | 460.40M | 386.80M | 358.57M | 407.58M | 364.18M | 335.93M | 301.08M | 220.22M | 148.69M | 96.03M | 15.70M | 27.00M | 3.20M | -50.24M |
| Net Income | 854.00M | 946.00M | 2.00B | 1.43B | 858.00M | 736.00M | 772.00M | 645.00M | 709.00M | 556.00M | 849.00M | 555.70M | 470.60M | 720.90M | 729.10M | 581.50M | 339.94M | 586.42M | 546.28M | 499.20M | 436.72M | 322.15M | 162.30M | 102.05M | -3.40M | 26.90M | -22.30M | -625.96M |
| Net Income Ratio | 9.23% | 9.57% | 18.49% | 15.16% | 11.11% | 9.77% | 10.01% | 8.58% | 9.46% | 7.48% | 11.88% | 7.53% | 6.27% | 9.78% | 9.78% | 8.02% | 5.07% | 9.35% | 9.93% | 9.74% | 9.22% | 7.84% | 4.47% | 2.98% | -0.15% | 1.84% | -1.46% | -38.73% |
| EPS | 7.59 | 8.12 | 15.90 | 10.68 | 6.38 | 5.41 | 5.63 | 4.58 | 4.92 | 3.83 | 5.58 | 3.49 | 2.95 | 4.08 | 3.91 | 2.99 | 1.76 | 2.98 | 2.71 | 2.45 | 2.11 | 1.67 | 0.87 | 0.57 | -0.03 | 0.23 | -0.19 | -5.33 |
| EPS Diluted | 7.52 | 7.98 | 15.53 | 10.52 | 6.29 | 5.29 | 5.50 | 4.51 | 4.87 | 3.81 | 5.54 | 3.46 | 2.92 | 4.05 | 3.87 | 2.97 | 1.74 | 2.94 | 2.66 | 2.35 | 2.02 | 1.62 | 0.83 | 0.54 | -0.03 | 0.22 | -0.19 | -5.33 |
| Weighted Avg Shares Out | 112.00M | 116.00M | 125.00M | 134.00M | 134.00M | 136.00M | 137.00M | 140.00M | 144.00M | 145.00M | 152.00M | 158.60M | 158.70M | 175.70M | 185.90M | 194.30M | 193.24M | 196.99M | 201.83M | 203.75M | 206.97M | 192.91M | 186.56M | 179.04M | 136.00M | 119.56M | 115.84M | 117.45M |
| Weighted Avg Shares Out (Dil) | 113.00M | 118.00M | 128.00M | 136.00M | 136.00M | 139.00M | 140.00M | 142.00M | 145.00M | 145.00M | 153.00M | 160.10M | 160.20M | 177.30M | 187.80M | 196.00M | 195.26M | 199.54M | 205.53M | 212.42M | 216.20M | 199.48M | 195.55M | 188.99M | 136.00M | 120.90M | 116.15M | 117.45M |
DGX Stock Rises on Q3 Earnings and Revenue Beat, 2024 Sales View Up
Quest Diagnostics' third-quarter 2024 performance reflects impressive DIS business growth and the benefits of new acquisitions.
Quest Diagnostics (DGX) Beats Q3 Earnings and Revenue Estimates
Quest Diagnostics (DGX) came out with quarterly earnings of $2.30 per share, beating the Zacks Consensus Estimate of $2.26 per share. This compares to earnings of $2.22 per share a year ago.
Quest Diagnostics beats quarterly results estimates on diagnostic test demand
Laboratory operator Quest Diagnostics beat Wall Street estimates for third-quarter profit and revenue on Tuesday, helped by robust demand for its diagnostic tests.
Quest Diagnostics Reports Third Quarter 2024 Financial Results; Updates Guidance for Full Year 2024
Third quarter revenues of $2.49 billion, up 8.5% from 2023 Third quarter reported diluted earnings per share ("EPS") of $1.99, up 1.5% from 2023; and adjusted diluted EPS of $2.30, up 3.6% from 2023 Full year 2024 revenues now expected...
Are Investors Undervaluing Quest Diagnostics (DGX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...
Quest Diagnostics (DGX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics Introduces Specimen Self-Collection for Common Genital Tract Infection Testing at Nationwide Network of Patient Service Centers
First-of-its-kind service empowers discreet and more convenient access to testing and treatment for vaginitis and similar genital tract infections such as chlamydia, gonorrhea, trichomoniasis and Mycoplasma genitalium Self-collection option available at no extra charge at any of Quest's 2,000 patient...
Quest Diagnostics: The Better Half Of An Emerging Healthcare Duopoly
Quest Diagnostics is a dominant player in the growing medical testing industry, offering consistent earnings and dividend growth with lower volatility. DGX benefits from secular tailwinds like aging populations and preventive medical testing, promising 10% annual returns and 6-8% annual...
DGX Gears Up for Q3 Earnings: What Lies Ahead for the Stock?
Quest Diagnostics is expected to deliver robust base business growth in the third quarter of 2024.
Quest Diagnostics Completes Acquisition of Lab Assets from OhioHealth
Goal to broaden access to cost-effective and innovative laboratory services in Ohio SECAUCUS, N.J. , Oct. 14, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that it has completed its previously announced acquisition of...
Source: https://incomestatements.info
Category: Stock Reports